A satellite symposium held at PBMI 2026.
To attend PBMI in person, register here
Program Information
Plaque psoriasis is a chronic, systemic immune-mediated inflammatory condition that results in profound clinical, psychosocial, and economic burden for affected patients. While management traditionally centers on topical therapies, many patients experience treatment failure or require escalation due to disease severity, significant body surface area involvement, or the presence of systemic comorbidities, such as psoriatic arthritis. This session focuses on gaps in the transition from topical to systemic therapy, specifically focusing on the evolving role of oral tyrosine kinase 2 (TYK2) inhibitors in plaque psoriasis. These selective small molecules modulate core inflammatory pathways, with a differentiated safety and efficacy profile compared with JAK inhibitors as well as different administration considerations compared with injectable biologics. Speakers will review safety and efficacy data for approved and emerging TYK2 inhibitors while sharing insights into how these oral options address treatment sequencing gaps in patient-centered care. Additionally, the faculty will utilize real-world patient scenarios to illustrate evidence-based escalation strategies while navigating complex managed care decision points such as prior authorization and step therapy requirements to optimize formulary strategies and support timely access to treatment for patients with moderate to severe plaque psoriasis.
Target Audience: Managed Care Pharmacists
Type of activity: Application
Release date: September
10, 2026
Expiration date: November 10, 2026
Time
to complete activity: 1 hour
Learner level: Foundational,
Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Describe the disease burden, clinical presentation, and underlying pathophysiology of plaque psoriasis, including the role of tyrosine kinase 2 (TYK2) in the inflammatory cascade
- Compare emerging TYK2 inhibitors with other systemic therapies for plaque psoriasis based on mechanisms of action and available clinical data
- Apply evidence-based criteria to inform appropriate transition from topical to systemic therapy
- Identify managed care strategies that support appropriate access to new and emerging therapies for patients with moderate to severe plaque psoriasis
